Study tracker · Healing · Eye
TB-500 / Thymosin beta-4
Updated 19 Oct 2026 · Peptilex evidence grade D / B (A = approved, large trials · D = mainly animal studies)
Thymosin beta-4 eye drops reached phase 3: in SEER-1 the cornea healed completely in 6 of 10 patients vs 1 of 8 on placebo; the global SEER-2 results are expected in late 2026. For TB-500 and injury recovery, the evidence comes from animal studies.
629PubMed papers
349Human studies
5Randomized trials
16Registered studies
2Ongoing / starting
5Phase 3+
Registered trials
From ClinicalTrials.gov, matched by name in the study title.
1 further registry entry from a sponsor we could not verify is not listed.
Latest randomized trials & key papers
From PubMed. The full story – mechanism, all results, risks – is in the TB-500 profile of the book.
- 2025Medical and surgical interventions for neurotrophic keratopathyKruoch Z et al. · The Cochrane database of systematic reviews · PMID 41347649
- 20220.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical TrialSosne G et al. · International journal of molecular sciences · PMID 36613994
- 2015Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trialSosne G et al. · Cornea · PMID 25826322
- 2010The effect of thymosin treatment of venous ulcersGuarnera G et al. · Annals of the New York Academy of Sciences · PMID 20536470
- 2010A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteersRuff D et al. · Annals of the New York Academy of Sciences · PMID 20536472
- 2007Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healingGuarnera G et al. · Annals of the New York Academy of Sciences · PMID 17495250
